ondansetron has been researched along with Carcinoma, Renal Cell in 1 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Carcinoma, Renal Cell: A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ondansetron or droperidol was given intravenously, 30 min prior to the first dose of IL-2 and then every 8 h for the duration of IL-2 treatment." | 2.67 | A randomized double-blinded comparison of the antiemetic efficacy of ondansetron and droperidol in patients receiving high-dose interleukin-2. ( Cole, DJ; Kim, H; Rosenberg, SA; Steinberg, SM; Weber, JS, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, H | 1 |
| Rosenberg, SA | 1 |
| Steinberg, SM | 1 |
| Cole, DJ | 1 |
| Weber, JS | 1 |
1 trial available for ondansetron and Carcinoma, Renal Cell
| Article | Year |
|---|---|
A randomized double-blinded comparison of the antiemetic efficacy of ondansetron and droperidol in patients receiving high-dose interleukin-2.
Topics: Adult; Aged; Carcinoma, Renal Cell; Droperidol; Female; Humans; Interleukin-2; Lymphoma, Non-Hodgkin | 1994 |